Kamada Ltd.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Kamada Ltd. (KMDA) is a vertically integrated global biopharmaceutical company focused on the research, development, manufacturing, and commercialization of specialty plasma-derived protein therapeutics. The company offers a diverse portfolio of proprietary FDA-approved products including GLASSIA for alpha-1 antitrypsin deficiency, KEDRAB for rabies post-exposure prophylaxis, CYTOGAM for cytomegalovirus prophylaxis in transplant patients, HEPAGAM B for hepatitis B post-exposure prophylaxis, VARIZIG for varicella-zoster virus prophylaxis, and WINRHO SDF for immune thrombocytopenic purpura and Rh hemolytic disease of the newborn; it also distributes additional plasma-derived products and biosimilars in Israel. Kamada operates in more than 30 countries including the U.S., Canada, Israel, Latin America, and Asia, leveraging FDA-approved manufacturing facilities for protein separation, formulation, and filling services. Founded in 1990 and headquartered in the Weizmann Science Park in Rehovot, Israel, Kamada employs approximately 450 people and lists on NASDAQ since 2013 and the Tel Aviv Stock Exchange since 2005, with FIMI Opportunity Fund as its largest shareholder holding about 21% of shares. In recent developments, Kamada has advanced its pivotal Phase 3 InnovAATe clinical trial for inhaled alpha-1 antitrypsin to treat AAT deficiency, expanded plasma collection operations, and executed business development including strategic M&A activities; the company affirmed 2024 financial guidance with strong profitability and projected double-digit revenue growth for 2025 driven by organic commercial expansion across its offerings in over 30 nations and ongoing plasma initiatives.
Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory
Kamada Q1 Earnings Call Highlights
Kamada Ltd. (KMDA) Q1 2026 Earnings Call Transcript
Kamada (KMDA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year
Stay Ahead of the Game With Kamada (KMDA) Q1 Earnings: Wall Street's Insights on Key Metrics
Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026
Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas
Kamada Ltd. (KMDA) Q4 2025 Earnings Call Transcript
Kamada (KMDA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Kamada (KMDA) Q4 Earnings and Revenues Miss Estimates
Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth
Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy
Ahead of Kamada (KMDA) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
KMDA vs. ARGX: Which Stock Is the Better Value Option?
KMDA or TECH: Which Is the Better Value Stock Right Now?
Kamada (KMDA) Soars 8.1%: Is Further Upside Left in the Stock?
Kamada (NASDAQ:KMDA) Stock Crosses Above 50 Day Moving Average – Here’s Why
Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender
Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook